ArticleChinese medicine2025
Discovery of an AKT1-targeting compound from a traditional herbal formula for alcoholic liver disease via integrative computational and experimental approaches.
Article in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dicaffeoylquinic acid alleviates alcoholic liver disease by targeting PLA2G4B and inhibiting the MAPK signaling pathway.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundAlcoholic liver disease (ALD) poses a major global health challenge, with limited effective interventions. The Dampness-Heat Regulating Formula (DRF), a traditional Chinese herbal tea composed of nine edible medicinal herbs, has shown promise in mitigating alcohol-induced liver injury. This study aimed to identify its core active components and elucidate underlying mechanisms.
methodsActive compounds were retrieved from multiple databases and screened using chemical similarity, target prediction, and ADMET filtering. Disease-related targets were identified through public transcriptomic datasets. Three machine learning algorithms-random forest, support vector machine, and LASSO-were used to prioritize therapeutic targets. High-throughput molecular docking and virtual screening were combined with untargeted metabolomics to identify candidate compounds. The interaction between oleanolic acid (OA) and AKT1 was further verified by cellular thermal shift assay (CESTA). In vitro and in vivo assays were conducted to validate hepatoprotective effects. Additionally, the content of OA in DRF was quantified by HPLC to assess the relevance of experimental dosing.
resultsA total of 690 candidate compounds and 33 ALD-associated targets were identified. AKT1 emerged as the top-ranked hub target. OA showed strong binding affinity to AKT1, and CESTA confirmed their direct interaction. Functional assays demonstrated that OA alleviated ethanol-induced damage in hepatocytes and zebrafish models. HPLC analysis confirmed that DRF contained physiologically relevant concentrations of OA, supporting the translational relevance of the selected doses.
conclusionThis study reveals a potential AKT1-centered mechanism through which DRF protects against ALD and identifies oleanolic acid as a bioactive compound with dual computational and experimental validation. It offers a scientific basis for integrating traditional herbal formulas with modern drug discovery approaches in the prevention of alcohol-related liver injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.